RADNOR, Pa., Feb. 4, 2023 (GLOBE NEWSWIRE) — The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the company has filed a Securities Class Action against Twist Bioscience Corporation (“Twist”) TWST on behalf of investors who have purchased or acquired between Twist common stock December 13, 2019 and November 14, 2022, inclusive (the “Class Period”). This action, titled Peters v. Twist Bioscience Corporation, et al.Case No. 3:22-cv-08168, filed in the United States District Court for the Northern District of California and assigned to the Honorable Edward J. Davila.

CLICK HERE TO SUBMIT YOUR TWIST LOSSES. YOU CAN ALSO CLICK OR COPY AND PASTE THE FOLLOWING LINK INTO YOUR BROWSER: https://www.ktmc.com/new-cases/twist-bioscience-corporation?utm_source=PR&utm_medium=link&utm_campaign=twst&mktm=r

TO SEE OUR VIDEO PLEASE CLICK HERE

LIMIT FOR THE PLAINTIFF: FEBRUARY 10, 2023

COURSE PERIOD: DECEMBER 13, 2019 TO NOVEMBER 14, 2022

CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
Jonathan Naji, Esq. (484) 270-1453 or toll free (844) 887-9500 or email info@ktmc.com

MISCONDUCT OF TWIST
Twist, a Delaware company headquartered in South San Francisco, California, is a biotechnology company that produces synthetic DNA and DNA products.

During the class period, the defendants repeatedly assured investors that the company had innovative proprietary technology related to its synthetic DNA products that positioned Twist for significant future growth. Similarly, defendants reported skyrocketing gross margins, allegedly rising from 12.8% in fiscal 2019 to 39.1% in fiscal 2021, with fiscal 2022 margins expected to hit 40%. During the Class Period, the Defendants also announced construction plans for a “Factory of the Future” in Wilsonville, Oregon (the “Oregon Facility”) that would allegedly provide hundreds of jobs and occupy 110,000 square feet. Through August 2022, the defendants forecast annual…